Rocket制药 RCKT 深 沪
等待开盘 05-20 09:30:00 美东时间
2.92
-0.150
-4.89%
华盛通- 最 高3.09
- 今 开3.07
- 成交量 293.31万股
- 最 低 2.90
- 昨 收 3.07
- 总市值 3.19亿
- 52周最高 5.45
- 市盈率 静 --
- 换手率 2.69%
- 52周最低 2.40
- 委 比 -87.73%
- 总股本 1.09亿
- 历史最高 67.48
- 量 比 1.36
- 振 幅 6.19%
- 历史最低 2.19
- 每 手 1
- 风险率 0.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Rocket Pharmaceuticals Q1 EPS $(0.42) Beats $(0.43) Estimate
Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.43) by 2.33 percent. This is a 25 percent increase over losses of $(0.56) per share
05-08 04:24
US FDA's accelerated approval for drugs needs more transparency, says research firm
US FDA's accelerated approval for drugs needs more transparency, says research firm By Sneha S K April 16 (Reuters) - The U.S. Food and Drug Administration should be more transparent when granting accelerated approval for certain drugs, influential drug pricing body, Institute for Clinical and Econo
04-16 20:00
美股大行评级 | 潜在涨幅172.14%！Alumis获Oppenheimer上调目标价至55美元；摩根大通首予希捷科技"超配"评级，目标价525美元
今日重点评级关注：Oppenheimer：维持Alumis"跑赢大市"评级，目标价从50美元升至55美元；美银证券：维持Rocket Pharmaceuticals"买入"评级，目标价从8美元升至9美元
03-31 16:30
BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Phathom, Argan
BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Phathom, Argan Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 27 (Reuters) - Wall Street's main indexes were on track to open lower
03-27 21:15
Why Is Rocket Pharma Stock Soaring Friday?
Rocket Pharmaceuticals stock jumps after FDA nod for Kresladi in LAD-I; voucher sale may boost cash runway and support growth plans.
03-27 21:13
美国FDA批准首款致命儿童罕见病疗法，火箭制药股价上涨
美国食品药品监督管理局（FDA）批准火箭制药（Rocket Pharmaceuticals）一款针对儿童罕见且通常致命的免疫缺陷疾病的基因疗法后，该公司股价...
03-27 20:06
The FDA Approves Rocket Pharmaceuticals' Kresladi For Pediatric Patients With Severe Leukocyte Adhesion Deficiency-I
First FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2Severe LAD-I is an ultra-rare, life-threatening pediatric genetic immunodeficiency characterized by recurrent infections
03-27 19:06
Rocket Pharma rises as FDA approves gene therapy
Rocket Pharmaceuticals (RCKT) added ~9% in the premarket on Friday after the U.S. Food and Drug Administration approved its gene therapy candidate Kresladi for a rare immune disease called leukocyte a...
03-27 18:48
美股夜盘 | 优品车涨40.80%，Globavend Holdings Ltd.涨40.78%
优品车涨40.80%；Globavend Holdings Ltd.涨40.78%；BeLive Holdings涨14.67%
03-27 15:01
